Based on the Arcellx Inc stock forecast from 10 analysts, the average analyst target price for Arcellx Inc is USD 99.50 over the next 12 months. Arcellx Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Arcellx Inc is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, Arcellx Inc’s stock price was USD 75.54. Arcellx Inc’s stock price has changed by -9.86% over the past week, -13.39% over the past month and +49.11% over the last year.
No recent analyst target price found for Arcellx Inc
No recent average analyst rating found for Arcellx Inc
Company Overview Arcellx Inc
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Read Less
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical tri...Read More
Frequently Asked Questions About Arcellx Inc (ACLX) Stock
Based on ratings from 10 analysts Arcellx Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 18 buy, sell and hold ratings.
Unfortunately we do not have enough data on ACLX's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for ACLX is USD 99.50 over the next 12 months. The maximum analyst target price is USD 136 while the minimum anlayst target price is USD 31.
Unfortunately we do not have enough data on ACLX's stock to indicate if its overvalued.
The last closing price of ACLX's stock was USD 75.54.
The most recent market capitalization for ACLX is USD 4.57B.
Based on targets from 10 analysts, the average taret price for ACLX is projected at USD 99.50 over the next 12 months.
This means that ACLX's stock price may go up by +31.72% over the next 12 months.
We can't find any ETFs which contains Arcellx Inc's stock.
As per our most recent records Arcellx Inc has 130 Employees.
Arcellx Inc's registered address is 800 Bridge Parkway, Redwood City, CA, United States, 94065.
You can get more information about it from Arcellx Inc's website at https://www.arcellx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Arcellx Inc (ACLX) Stock
Based on ratings from 10 analysts Arcellx Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 18 buy, sell and hold ratings.
Unfortunately we do not have enough data on ACLX's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for ACLX is USD 99.50 over the next 12 months. The maximum analyst target price is USD 136 while the minimum anlayst target price is USD 31.
Unfortunately we do not have enough data on ACLX's stock to indicate if its overvalued.
The last closing price of ACLX's stock was USD 75.54.
The most recent market capitalization for ACLX is USD 4.57B.
Based on targets from 10 analysts, the average taret price for ACLX is projected at USD 99.50 over the next 12 months.
This means that ACLX's stock price may go up by +31.72% over the next 12 months.
We can't find any ETFs which contains Arcellx Inc's stock.
As per our most recent records Arcellx Inc has 130 Employees.
Arcellx Inc's registered address is 800 Bridge Parkway, Redwood City, CA, United States, 94065.
You can get more information about it from Arcellx Inc's website at https://www.arcellx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ACLX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
